Press release
Lawsuit filed for Investors who lost money with shares of ESSA Pharma Inc. (NASDAQ: EPIX)

A lawsuit was filed on behalf of investors in ESSA Pharma Inc. (NASDAQ: EPIX) shares over alleged securities laws violations.
Investors who purchased shares of ESSA Pharma Inc. (NASDAQ: EPIX) have certain options and for certain investors are short and strict deadlines running. Deadline: March 25, 2025. NASDAQ: EPIX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Canada based ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. At all relevant times the Company's lead product candidate was masofaniten (EPI-7386), an investigational, oral, small molecule inhibitor of the androgen receptor, which plays a pivotal role in the development and progression of prostate cancer, especially castration-resistant prostate cancer ("CRPC").
ESSA Pharma Inc. was evaluating masofaniten in various clinical trials as a monotherapy and combination therapy for the treatment of prostate cancer. These trials included, among others, EPI-7386-CS-010 (the "M-E Combination Study"), a Phase 1/2 study of masofaniten in combination with enzalutamide compared with enzalutamide alone in patients with metastatic CRPC.
Phase 1 of the M-E Combination Study was a single-arm dose escalation study of masofaniten in combination with a fixed dose of enzalutamide. Based on results from the Phase 1 portion of the M-E Combination Study, ESSA purportedly identified a recommended Phase 2 combination dose of masofaniten 600 mg twice daily combined with enzalutamide 160 mg once daily ("QD"). Phase 2 of the M-E Combination Study compared this recommended combination dose with a 160 mg QD enzalutamide monotherapy-the standard of care for the intended patient population. The primary endpoint of Phase 2 of the M-E Combination Study was the proportion of patients reaching "PSA90," which refers to deep prostate-specific antigen ("PSA") response with a greater than or equal to 90% decline in PSA. PSA90 is an important indicator of a patient's response to prostate cancer treatment.
Because masofaniten was ESSA's lead and most advanced product candidate, establishing its clinical, regulatory, and commercial viability was of central importance to Defendants and investors alike. Indeed, according to ESSA's website, apart from masofaniten, the Company only has two other product candidates, each of which is still in early development at either the research or preclinical stage
ESSA Pharma Inc. reported that its Total Revenue rose from over $32.13 billion for the 12 months period that ended on September 30, 2023, to over $34.42 billion for the 12 months period that ended on September 30, 2024, and that its Net Loss over those respective time periods increased from over $26.45 billion to $28.54 billion.
On October 31, 2024, during after-market hours, ESSA Pharma Inc announced its decision to terminate Phase 2 of the M-E Combination Study, citing "a protocol-specified interim review of the safety, PK [pharmacokinetics] and efficacy data, which showed a much higher rate of PSA90 response in patients treated with enzalutamide monotherapy . . . than were expected based upon historical data" and "no clear efficacy benefit seen with the combination of masofaniten plus enzalutamide compared to enzalutamide single agent." The Company further advised that "a futility analysis determined a low likelihood of meeting the prespecified primary endpoint of the study" and that, "[a]s part of the effort to focus its resources," it was "planning to terminate the other remaining company-sponsored and investigator-sponsored clinical studies evaluating masofaniten either as a monotherapy or in combination with other agents."
Shares of ESSA Pharma Inc. (NASDAQ: EPIX) declined from $10.25 per share on February 15, 2024, to $1.40 per share on November 01, 2024.
The plaintiff claims that between December 12, 2023 and October 31, 2024, the Defendants made false and/or misleading statements and/or failed to disclose that masofaniten in combination with enzalutamide had no clear efficacy benefit over enzalutamide alone, that accordingly, masofaniten in combination with enzalutamide was less effective in treating prostate cancer than Defendants had led investors to believe, that the M-E Combination Study was unlikely to meet its prespecified Phase 2 primary endpoint, that accordingly, Defendants had overstated masofaniten's clinical, regulatory, and commercial prospects, and that as a result, Defendants' public statements were materially false and misleading at all relevant times.
Those who purchased shares of ESSA Pharma Inc. (NASDAQ: EPIX) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lawsuit filed for Investors who lost money with shares of ESSA Pharma Inc. (NASDAQ: EPIX) here
News-ID: 3867999 • Views: …
More Releases from Shareholders Foundation, Inc.

Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced.
Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for long term investors in…

Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…

CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc.
Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at…

Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for ESSA
Investors who hold shares of ESSA Pharma Inc. (NASDAQ: EPIX) Long Term should co …
An investigation was announced for long-term investors in shares of ESSA Pharma Inc. (NASDAQ: EPIX) concerning potential breaches of fiduciary duties by certain directors of ESSA Pharma Inc.
Investors who are current long term investors in ESSA Pharma Inc. (NASDAQ: EPIX) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
ESSA Pharma Inc. (NASDAQ: EPIX) Investor Alert: Deadline in Lawsuit on March 25, …
A deadline is coming up on March 25, 2025 in the lawsuit filed for certain investors of ESSA Pharma Inc. (NASDAQ: EPIX) over alleged securities laws violations by ESSA Pharma Inc.
Investors who purchased shares of ESSA Pharma Inc. (NASDAQ: EPIX) have certain options and there are strict and short deadlines running. Deadline: March 25, 2025. NASDAQ: EPIX stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
KOBI Achieves ESSA Tier IV Validation: Advancing Standards in Dyslexia Education
Salt Lake City, Utah - January 16 2025 - KOBI, the innovative reading app designed specifically for children with dyslexia, has achieved ESSA Tier IV validation, marking a significant milestone in its mission to meet the highest educational standards. This recognition validates KOBI's dedication to creating effective, evidence-based tools that address the unique challenges faced by children with dyslexia and other learning differences.
Children with dyslexia often require more time…
A beacon of hope for The Gambia: human rights lawyer Essa Faal and his vision fo …
The Gambia, a small country in West Africa with great potential, could be on the brink of a historic turning point. Essa Faal, a renowned human rights lawyer and internationally recognised jurist, has decided to stand as a presidential candidate. His goal: to fundamentally reform The Gambia and create a better future for the population.
Mr. Faal: a symbol of a better future of all Gambians
Essa Mbye Faal is a symbol…
Human rights attorney Essa Mbye Faal: The Gambia's New Hope in the 2026 Presiden …
The Gambia. The smallest country in Africa is a popular holiday destination for Europeans, has great bathing weather all year round and a very beautiful river landscape of the eponymous Gambia River.... There are crocodiles, hippos, monkeys and more than 500 species of fish and birds of all colours and sizes. Many Europeans from all countries also travel to The Gambia time and again to enjoy the sun and the…
ESSA Group continues to invest in 2021 and announces new projects for developmen …
ESSA Group, one of the biggest players in trade marketing and sales services on the Romanian market, has several ongoing projects to consolidate its business lines, after a year full of challenges - 2020, where the whole business had to be recalibrated and proper actions needed to be taken according to the pandemic context. Founded a decade ago by Eugen Saulea, ESSA Group reported a turnover of 15 million euros…